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LETTERS TO THE EDITOR
Peripheral Neuropathy with
Infliximab Therapy in
Inflammatory Bowel Disease
To the Editor:
Antitumor necrosis factor alpha (anti-
TNF) agents have provided an important
breakthrough in the management of patients
with inflammatory bowel disease (IBD),
leading to high remission rates, fistula clo-
sure, and improved quality of life. However,
they are not without serious adverse effects,
including lymphoma, infection, bowel ob-
struction, and neuropathy.1 This case report
illustrates a rare and clinically significant
side effect of peripheral neuropathy occur-
ring with anti-TNF therapy for Crohn’s
disease (CD).
A 57-year-old woman with long-
standing ileocolonic CD presented with a
flare characterized by frequent (up to 10
times per day), loose stool, with nocturnal
diarrhea and crampy abdominal pain. Inves-
tigations revealed a culture-negative stool
with erythrocytes and white blood cells,
raised inflammatory markers (C-reactive
protein [CRP] 113, platelets 550) and evi-
dence of active ileocolonic inflammation on
endoscopic and histological inspection. The
patient’s medical management had previ-
ously been limited because of adverse reac-
tions to thiopurines (pancreatitis with mer-
captopurine) and methotrexate (nausea,
vomiting, and headaches). Oral steroid ther-
apy failed to control this flare and the patient
was hospitalized for ongoing symptoms.
Subsequently, the patient was started on an-
ti-TNF therapy (infliximab 5 mg/kg) and
after 2 doses the patient had significant clin-
ical improvement. Her bowel symptoms re-
solved, inflammatory markers normalized
(CRP 3.6, platelets 372), with endoscopic
evidence of healing and reduced histological
activity.
On day 3 after the initial infusion she
suffered from flu-like symptoms and devel-
oped a dry, pruritic rash on her upper limbs
which resolved over a week. Day 6 after the
second infusion the patient reported aching
of the low back and lower limbs, with
numbness and paresthesia of the toes, and
burning of the feet. Examination revealed a
tandem gait ataxia, reduced power, and loss
of light touch with diminished pain, propri-
oception, and vibration sense to the level of
the ankles. Her lower limbs were areflexic,
with nonresponsive plantars and a positive
Romberg sign. Nerve conduction studies re-
vealed a severe sensory motor neuropathy.
Investigations including antinuclear antibod-
ies (ANA), extractable nucleic acid (ENA),
erythrocyte sedimentary rate (ESR), anti
neutrophil cytoplasmic antibody (ANCA),
double stranded DNA (dsDNA), anti-neuro-
nal nucleus 1 (anti-Hu), anti-neuronal nu-
cleus 2 (anti-Ri), purkinje cell antibody (an-
ti-Yo), purkinje cell antibody (anti-PCA-2),
thyroid stimulating hormone (TSH), glu-
cose, vitaminB12, folate, anti tissue transglu-
taminase (anti-TTG), and chest computed
tomography (CT)werewithin normal limits.
Serum protein electrophoresis on several oc-
casions over 6 months demonstrated an IgG
kappa monoclonal band of 2.0 g/L. The
patient’s clinical presentation was consistent
with a generalized axonal neuropathy, and
following withdrawal of the anti-TNF
agent her neurological symptoms and signs
resolved over a period of 4 months.
The time course of this adverse
event makes it very likely that it was due
to the infliximab therapy. Axonal poly-
neuropathy has been reported with
TNF antibody treatment of rheumatoid
arthritis but as far as we are aware it has
not been reported with treatment of CD
or ulcerative colitis.2
Despite the high levels of TNF
found in the cerebral spinal fluid and brain
plaques of multiple sclerosis patients, anti-
TNF therapy is not effective in this condi-
tion. In a randomized, placebo-controlled
trial involving 168 multiple sclerosis pa-
tients, Lenercept, a p55 TNF receptor fusion
protein, resulted in increased disease activity
with higher relapse rates.3 Moreover, inflix-
imab therapy is associated with an increased
number of new gadolinium-enhancing le-
sions onmagnetic resonance imaging (MRI)
in multiple sclerosis patients.4 Case re-
ports of peripheral neurological complica-
tions arising in patients with rheumatoid
arthritis include Guillain–Barre syndrome,
chronic demyelinating polyradiculoneu-
ropathy, multifocal motor neuropathy
with conduction block, and mononeuritis
simplex/multiplex.2,5–7
In summary, central and periph-
eral neuropathies are rare but recognized
side effects of TNF monoclonal anti-
body therapy. However, neuropathies
are not commonly mentioned with re-
gard to complications of TNF mono-
clonal antibody treatment in the IBD
literature. Axonal neuropathy in partic-
ular has not been reported with TNF
monoclonal antibody treatment of IBD,
and we draw this to the attention of our
gastroenterology colleagues.
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